See more : Old Mutual Limited (OMU.L) Income Statement Analysis – Financial Results
Complete financial analysis of Ensysce Biosciences, Inc. (ENSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ensysce Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- DCW Limited (DCW.NS) Income Statement Analysis – Financial Results
- Falcon Invest – Falcon Danske Aktier Momentum (FIIDKM.CO) Income Statement Analysis – Financial Results
- Hangzhou Haoyue Personal Care Co., Ltd (605009.SS) Income Statement Analysis – Financial Results
- American Water Works Company, Inc. (0HEW.L) Income Statement Analysis – Financial Results
- Golden Band Resources Inc. (GBRIF) Income Statement Analysis – Financial Results
Ensysce Biosciences, Inc. (ENSC)
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.23M | 2.52M | 3.53M | 3.93M | 1.76M | 0.00 | 0.00 |
| Cost of Revenue | 7.59M | 19.84M | 151.00 | 1.37M | 3.33M | 1.56M | 0.00 |
| Gross Profit | -5.36M | -17.31M | 3.53M | 2.56M | -1.56M | -1.56M | 0.00 |
| Gross Profit Ratio | -240.17% | -686.08% | 100.00% | 65.18% | -88.70% | 0.00% | 0.00% |
| Research & Development | 7.59M | 19.84M | 4.69M | 4.39M | 3.40M | 0.00 | 0.00 |
| General & Administrative | 5.36M | 6.91M | 18.71M | 1.15M | 6.93M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -3.60M | 0.00 | 0.00 |
| SG&A | 5.36M | 6.91M | 18.71M | 1.15M | 3.33M | 1.56M | 146.70K |
| Other Expenses | -7.59M | -2.52M | -3.53M | -3.93M | 0.00 | 600.00K | 0.00 |
| Operating Expenses | 5.36M | 24.22M | 19.87M | 1.61M | 3.33M | 959.25K | 146.70K |
| Cost & Expenses | 12.95M | 24.22M | 19.87M | 1.61M | 3.33M | 959.24K | 146.70K |
| Interest Income | 0.00 | 1.25M | 3.22M | 719.65K | 4.25M | 3.63M | 0.00 |
| Interest Expense | 353.95K | 109.53K | 1.30M | 995.50K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 151.00 | 151.00 | 201.00 | 201.00 | 161.14K | 0.00 |
| EBITDA | -10.72M | -24.22M | -19.87M | -1.61M | 921.15K | 2.68M | -27.56K |
| EBITDA Ratio | -480.52% | -959.91% | -562.71% | -41.03% | -188.70% | 0.00% | 0.00% |
| Operating Income | -10.72M | -24.22M | -19.87M | -1.61M | -3.33M | -959.24K | -146.70K |
| Operating Income Ratio | -480.52% | -959.91% | -562.71% | -41.04% | -188.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | 91.91K | 14.41K | -9.28M | 1.45M | 4.25M | 3.64M | 119.14K |
| Income Before Tax | -10.63M | -24.21M | -29.15M | -160.88K | 921.15K | 2.68M | -27.56K |
| Income Before Tax Ratio | -476.40% | -959.33% | -825.38% | -4.09% | 52.22% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 753.88K | -151.00 | 777.85K | -555.20K | 553.92K | 3.64K |
| Net Income | -10.61M | -24.96M | -29.15M | -938.73K | 1.48M | -1.34M | -31.19K |
| Net Income Ratio | -475.81% | -989.21% | -825.38% | -23.88% | 83.70% | 0.00% | 0.00% |
| EPS | -4.69 | -138.73 | -346.90 | -14.29 | 15.02 | -12.91 | -0.30 |
| EPS Diluted | -4.69 | -138.73 | -346.90 | -13.65 | 15.02 | -12.91 | -0.30 |
| Weighted Avg Shares Out | 2.26M | 179.93K | 84.02K | 65.70K | 98.26K | 104.02K | 105.00K |
| Weighted Avg Shares Out (Dil) | 2.26M | 179.93K | 84.02K | 68.78K | 98.26K | 104.02K | 105.00K |
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
Ensysce Biosciences Reports First Quarter 2024 Financial Results
Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Source: https://incomestatements.info
Category: Stock Reports